CDSCO Panel grants Bristol Myer Squibb's Proposal for Additional Indication of anti-cancer drug Nivolumab Dr. Divya Colin30 Jan 2024 5:30 PM ISTNew Delhi: Noting that sufficient safety data is established, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Bristol Myers Squibb concludes acquisition of Mirati Therapeutics Ruchika Sharma26 Jan 2024 12:15 PM ISTThe transaction is expected to be treated as a business combination and to be dilutive to Bristol Myers Squibb's non-GAAP earnings per share by...
Bristol Myers Squibb Repotrectinib application to treat cancer validated by EMA Ruchika Sharma4 Jan 2024 1:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its marketing authorization application...
Bristol Myers Squibb to acquire RayzeBio for USD 4.1 billion Ruchika Sharma28 Dec 2023 1:30 PM ISTPrinceton: Bristol Myers Squibb and RayzeBio, Inc. have announced a definitive merger agreement under which Bristol Myers Squibb will acquire...
Bristol Myers Squibb to acquire Karuna Therapeutics for USD 14 billion Ruchika Sharma25 Dec 2023 2:30 PM ISTPrinceton: Bristol Myers Squibb and Karuna Therapeutics, Inc. have announced that they have entered into a definitive merger agreement under...
Bristol Myers Squibb to discontinue trial for colorectal cancer treatment Ruchika Sharma17 Dec 2023 2:45 PM ISTPrinceton: Bristol Myers Squibb has announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and...
Bristol Myers Squibb, SystImmune collaborate for development, commercialization of BL-B01D1 Ruchika Sharma12 Dec 2023 12:30 PM ISTPrinceton: SystImmune, a clinical-stage biopharmaceutical company, and Bristol Myers Squibb have announced an exclusive license and collaboration...
Bristol Myers Squibb Abecma approved for use in earlier lines of therapy for patients with relapsed or refractory Multiple Myeloma in Japan Ruchika Sharma7 Dec 2023 4:30 PM ISTTokyo: Bristol-Myers Squibb K.K. has announced that the company has received manufacturing and marketing approval of the supplemental New Drug...
USFDA accepts for priority review Bristol Myers Squibb application for Opdivo plus Cisplatin-Based Chemotherapy for urothelial carcinoma Ruchika Sharma7 Dec 2023 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License...
US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy Ruchika Sharma21 Nov 2023 2:30 PM ISTThe therapy was originally co-developed by bluebird bio but following its spin-off in 2021 became part of 2seventy's portfolio.
USFDA nod to Bristol Myers Squibb Augtyro for lung cancer Ruchika Sharma16 Nov 2023 5:30 PM ISTAugtyro is designed to minimize interactions that can lead to certain forms of treatment resistance in ROS1-positive metastatic NSCLC patients.
Bristol Myers Squibb acquires Orum Therapeutics blood cancer therapy for up to USD 180 million Ruchika Sharma7 Nov 2023 3:30 PM ISTUnited States: Bristol Myers Squibb has acquired Orum Therapeutics' experimental therapy to treat a type of blood cancer for a total value of up to...
